UCB’s Neupro Returns To U.S. Market With New Formulation, Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves a new version of UCB’s skin patch for treatment of advanced Parkinson’s disease and restless leg syndrome. The new product, which contains different excipients to prevent crystallization, will be available in July.
You may also be interested in...
Belgium's UCB Is Almost Over Its Patent Cliff, But Guides Revenues And Profits To Decline In 2012
UCB Pharma's trio of new products is managing, for now, to compensate for the generic erosion to its best-selling anti-epileptic Keppra.
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.